Total Health
J

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 ASCO® Direct Philadelphia

By Total Health FEATURING Jessica Bauman
By Total Health FEATURING Jessica Bauman
0 views
September 29, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Recommended

AUTOPLAY
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
16:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

Feat. L. Raez
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

Feat. V. Subbiah
14:49
Vivek Subbiah

Year in Review: Precision Medicine

13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
09:37
Luis Raez

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West